Holen Sie sich die Stockscreener-App
21.80
0.05%
0.01
Handel nachbörslich:
21.80
Schlusskurs vom Vortag:
$21.79
Offen:
$22.11
24-Stunden-Volumen:
1.18M
Relative Volume:
0.62
Marktkapitalisierung:
$2.70B
Einnahmen:
$247.00M
Nettoeinkommen (Verlust:
$-249.00M
KGV:
-7.055
EPS:
-3.09
Netto-Cashflow:
$-267.00M
1W Leistung:
+3.76%
1M Leistung:
-1.80%
6M Leistung:
+135.42%
1J Leistung:
+54.39%
1-Tages-Spanne:
$21.53
$22.45
1-Wochen-Bereich:
$20.64
$24.59
52-Wochen-Spanne:
$6.50
$26.40
Arcus Biosciences Inc Stock (RCUS) Company Profile
Firmenname
Arcus Biosciences Inc
Sektor
Branche
Telefon
(510) 694-6200
Adresse
3928 POINT EDEN WAY, HAYWARD, CA
Vergleichen Sie RCUS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RCUS
Arcus Biosciences Inc
|
21.80 | 2.70B | 247.00M | -249.00M | -267.00M | -3.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Arcus Biosciences Inc Stock (RCUS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-13 | Hochstufung | Goldman | Neutral → Buy |
| 2026-01-08 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-02-26 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2024-10-21 | Eingeleitet | H.C. Wainwright | Neutral |
| 2024-10-08 | Eingeleitet | Wells Fargo | Overweight |
| 2022-11-18 | Eingeleitet | BofA Securities | Neutral |
| 2022-10-11 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-10-15 | Fortgesetzt | BTIG Research | Buy |
| 2020-11-24 | Eingeleitet | Berenberg | Buy |
| 2020-11-23 | Eingeleitet | Evercore ISI | Outperform |
| 2020-04-03 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-09-27 | Eingeleitet | Mizuho | Buy |
| 2019-05-24 | Fortgesetzt | Citigroup | Buy |
| 2018-10-09 | Eingeleitet | Wedbush | Outperform |
| 2018-04-09 | Eingeleitet | Citigroup | Buy |
| 2018-04-09 | Eingeleitet | Goldman | Neutral |
| 2018-04-09 | Eingeleitet | Leerink Partners | Outperform |
Alle ansehen
Arcus Biosciences Inc Aktie (RCUS) Neueste Nachrichten
Arcus Biosciences appoints new Chief Medical Officer - MSN
Arcus Biosciences (NYSE:RCUS) Trading Down 5.8%Time to Sell? - MarketBeat
Is Arcus Biosciences (RCUS) Using Casdatifan to Quietly Redefine Its Core Oncology Strategy? - Sahm
Goldman Sachs Upgrades Arcus Biosciences (RCUS) to 'Buy', Raises Price Target | RCUS Stock News - GuruFocus
Goldman Sachs Upgrades Arcus Biosciences (RCUS) - Nasdaq
Understanding the Setup: (RCUS) and Scalable Risk - Stock Traders Daily
Arcus Biosciences stock jumps on Goldman upgrade as traders eye JPM Healthcare stage - TechStock²
Arcus Biosciences (NYSE:RCUS) Shares Gap UpHere's What Happened - MarketBeat
Goldman Sachs resumes Arcus Biosciences stock coverage with Buy rating By Investing.com - Investing.com Nigeria
Goldman Sachs resumes Arcus Biosciences stock coverage with Buy rating - Investing.com India
Risk Check: What is Arcus Biosciences Incs valuation compared to sectorJuly 2025 Big Picture & High Accuracy Investment Signals - baoquankhu1.vn
Arcus downgraded at Morgan Stanley on balanced risk-reward setup - MSN
Arcus Biosciences (RCUS) Valuation Check After Recent Share Price Pullback And 1 Year Gain - Yahoo Finance
Los Angeles Daily NewsArcus Biosciences, Inc. Common Stock (NYSE:RCUS) Stock Quote - FinancialContent
Can Arcus Biosciences Inc. stock double in next 5 yearsMarket Performance Recap & AI Enhanced Trade Execution Alerts - Улправда
Arcus Biosciences (RCUS) CEO Terry Rosen donates 35,000 shares in Form 4 - Stock Titan
Will Arcus Biosciences Inc. stock recover faster than marketMarket Movers & Weekly High Return Forecasts - ulpravda.ru
Arcus Biosciences, Inc. (RCUS) Investor Outlook: Exploring A 48.95% Upside Potential - DirectorsTalk Interviews
Arcus Biosciences, Inc. (NYSE:RCUS) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Will Arcus Biosciences Inc. stock continue upward momentumWatch List & AI Optimized Trade Strategies - ulpravda.ru
Is Arcus Biosciences Inc. stock a buy for dividend growthWeekly Market Outlook & Smart Allocation Stock Tips - Улправда
Growth Review: Is Arcus Biosciences Inc. stock a buy for dividend growth2025 Trading Volume Trends & Fast Moving Stock Trade Plans - Улправда
Arcus Biosciences (RCUS) Downgraded by Morgan Stanley Amid Recen - GuruFocus
Is Arcus Biosciences Inc. stock attractive after correctionMarket Sentiment Report & Precise Trade Entry Recommendations - ulpravda.ru
Arcus Biosciences (NYSE:RCUS) stock slides on Morgan Stanley downgrade as casdatifan 2026 timeline sharpens - TechStock²
BlackRock (RCUS) Schedule 13G/A shows 12.7M Arcus Biosciences shares owned - Stock Titan
Will Arcus Biosciences Inc. stock maintain growth storyJuly 2025 Earnings & Accurate Buy Signal Alerts - Улправда
Arcus stock downgraded at Morgan Stanley (RCUS:NYSE) - Seeking Alpha
Arcus Biosciences (NYSE:RCUS) Shares Gap Down on Insider Selling - MarketBeat
Morgan Stanley Downgrades Arcus Biosciences (RCUS), Adjusts Pric - GuruFocus
Morgan Stanley downgrades Arcus Biosciences stock on balanced risk/reward - Investing.com Canada
Insider Selling: Arcus Biosciences (NYSE:RCUS) President Sells 31,823 Shares of Stock - MarketBeat
Arcus Biosciences (RCUS) Sets Ambitious 2026 Agenda for Casdatif - GuruFocus
Biotech outlines 2026 plans for kidney cancer and atopic dermatitis - Stock Titan
Arcus Biosciences President Sells $2 Million as Stock Delivers 48% Annual Return - Yahoo Finance
RCUS (NYSE: RCUS) trust files Rule 144 to sell 31,823 Class A shares - Stock Titan
RCUS SEC FilingsArcus Bioscience 10-K, 10-Q, 8-K Forms - Stock Titan
Arcus Biosciences (RCUS) Shares Fall by Over 9% - GuruFocus
Arcus Biosciences (NYSE:RCUS) Trading Down 7.8% Following Insider Selling - MarketBeat
Portfolio Shifts: Is Arcus Biosciences Inc stock a buy for dividend growthLong Setup & AI Powered Buy and Sell Recommendations - Bộ Nội Vụ
Insider Sell: Goeltz II Robert C. Sells Shares of Arcus Bioscien - GuruFocus
Arcus Biosciences appoints new board member - MSN
Insider Selling: Arcus Biosciences (NYSE:RCUS) CFO Sells 6,552 Shares of Stock - MarketBeat
Arcus Biosciences (RCUS) CFO reports 6,552-share sale under 10b5-1 plan - Stock Titan
Arcus Biosciences (RCUS) CEO moves 2,400 shares to family trusts - Stock Titan
The Technical Signals Behind (RCUS) That Institutions Follow - Stock Traders Daily
Arcus Biosciences (NYSE:RCUS) Trading Up 2.8%Should You Buy? - MarketBeat
Certain Common Stock of Arcus Biosciences, Inc. are subject to a Lock-Up Agreement Ending on 30-DEC-2025. - marketscreener.com
Certain Stock Optios of Arcus Biosciences, Inc. are subject to a Lock-Up Agreement Ending on 30-DEC-2025. - marketscreener.com
Certain Restricted Stock Units of Arcus Biosciences, Inc. are subject to a Lock-Up Agreement Ending on 30-DEC-2025. - MarketScreener
Arcus Biosciences Earnings Notes - Trefis
Finanzdaten der Arcus Biosciences Inc-Aktie (RCUS)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.73%
0.92%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):